Summary HuIL-6 cDNA, cloned into a neomycin resistant conferring expression vector, BMGNeo, was transfected into Lewis Lung Carcinoma (LLC) cells. LLC cells (5 x 106 ml-X) transfected with IL-6 cDNA (LLC-IL6) secreted IL-6 into the culture supernatant at a concentration of 9.9 ngml-' within 48 h. When 1,000,000 of untransfected LLC, BMGNeo vector transfected LLC (LLC-Neo) or LLC-1L6 cells were transplanted into C57BL/6 mice subcutaneously, the mean ± s.d. of survival times of these mice were 33.3 ± 9.7, 34.3 ± 7.1 and 17.0 ± 3.1 days, respectively. The survival time of LLC-1L6 cells transplanted mice was significantly shorter than that of LLC (P<0.01) or LLC-Neo (P<0.01) cells transplanted mice without a measurable difference of tumour size. Plasma concentration of IL-6 steadily increased in LLC-IL6 transplanted mice. Body weight and serum albumin were significantly lower in LLC-1L6 transplanted mice than in LLC transplanted mice. Mouse IL-la and mouse TNF-a were not detected in the plasma of LLC-1L6 transplanted mice. These data suggested that secretion of IL-6 from LLC cells was unable to alter net tumour growth rate but rather caused a state similar to cachexia without detectable increase of IL-Ia and TNF-a in the plasma. This state may be responsible for the shortened survival of LLC-1L6 tumour-bearing mice.
IL-6 is multifunctional cytokine which was originally identified as a B cell differentiation factor, B-cell stimulatory factor 2 (BSF-2) (Hirano et al., 1986; Snick, 1990) . This molecule, which is produced by many different cells, is also known as IFN-P2, hybridoma/plasmacytoma growth factor (HPGF), plasmacytoma growth factor (PCT-GF), hepatocyte-stimulating factor (HSF), 26-kDa protein and cytotoxic T-cell differentiation factor (CDF) (Snick, 1990) . can act as a cytotoxic T cell differentiation factor as well as a stimulatory factor for T and B cells and enhances the cytotoxic activity of NK cells via IL-2 (Luger et al., 1989) . IL-6 acts predominantly by enhancing IL-2 responsiveness whereas IL-1 acts predominantly on IL-2 production (Snick, 1990) . Indeed an anti-tumour effect of human recombinant IL-6 in mice bearing syngenic tumour has been reported (Mule et al., 1990; Kitahara et al., 1990) . Thus, IL-6 is considered to be one of the important factors for the rejection of cancer cells and the development of immunotherapy for cancer patients.
The local secretion of cytokine from tumour cells may more effectively induce an immune response against cancer cells than systemic administration because of higher and stable concentration at the tumour site. Indeed it has been reported that an effective immune response can be induced in syngenic mice by the transplantation of cytokine producing tumours transfected with cDNAs coding for cytokines such as IL-2, IL-4, IL-7, P-, y-IFN, tumour necrosis factor (TNF)-a and granulocyte colony-stimulating factor (G-CSF) (Mizuno et al., 1990; Gansbacher et al., 1990; Teng et al., 1991; Asher et al., 1991; Blankenstein et al., 1991; Colombo et al., 1991) . However, the induction of an immune response by the tumour cells transfected with IL-6 cDNA is still controversial (Blankenstein et al., 1991; Okada, 1990) . Thus, in order to examine the effect of IL-6 cDNA transfection to tumour cells we have transfected human IL-6 cDNA into a spontaneous murine lung cancer, Lewis Lung Carcinoma (LLC) cells (Sugiura & Stock, 1955; Merriman et al., 1989) and tested its effect on potential tumour rejection.
Materials and methods

Mice
Inbred 5-week-old female C57BL/6 mice were obtained from Japan Charles River Co., Ltd. (Atsugi, Japan). These were maintained under specific-pathogen-free conditions in our laboratory.
Cell lines and culture LLC cells originated as a spontaneous carcinoma of the lung in a C57BL/6 mouse (Sugiura et al., 1955; Merriman et al., 1989) . LLC cells and transfected LLC cells were cultured in Iscove medium (IBL, Fujioka, Japan) with 20% FCS (IBL, Fujioka, Japan). (Felgner et al., 1987 Biochemical analysis of the serum Total protein, albumin, blood urea nitrogen, creatinine, triglyceride, total cholesterol, free fatty acid, cholinesterase, calcium and phosphate were assayed using an automatic analyser (HITACHI, model 736).
Monoclonal antibody Anti-human IL-6 mAb, SK2 was established as previously described (Galfre et al., 1977) . Eight-week-old female BALB/ c mice were immunised with 10 jg of recombinant human IL-6 at day 1, 14, 22 and 28. Hybridomas of spleen cell and the murine myeloma cell line, P3UI, were established using polyethylene glycol. An anti-human IL-6 mAb producing clone was isolated and injected into mice intraperitoneally for ascites production. Purified IgG was obtained from the ascites using a protein A agarose column. 0.41 lgg ml-' of anti-human IL-6 mAb, SK2 could neutralise 1 ng ml-' of IL-6.
Macroscopical and pathological examination All the organs of dissected animals were macroscopically examined and histological examinations were done for liver, spleen, lung, heart and kidney 14 days after transplantation.
Statistical analysis
The data of body weight and serum albumin were analysed for significance by the two-tailed t-test. The survival curve of each group was analysed by log rank test. P values were calculated by comparison of experimental groups.
Results
Characteristics of transfected LLC BMGNeo and BMGNeo-IL6 were transfected into LLC cells using lipofectin and successful transfectants were selected in 1 mg ml-' of G418 containing medium. Doubling times of LLC, BMGNeo transfected LLC (LLC-Neo) and BMGNeo-IL6 transfected LLC (LLC-IL6) cells were 20.4, 20.6 and 23.2 h, respectively. The morphology of transfected LLC cells was identical to that of non transfected LLC cells both in vitro and in vivo. Cells were cultured for 48 h at 5 x 106 cells ml-' to produce supernatants which were used for assaying IL-6 content. The supernatant of LLC-IL6 cells contained 9.9 ng ml-' of IL-6, whereas no IL-6 was detected in the supernatants of LLC and LLC-Neo cells.
Tumour growth in C57BL/6 mice In vivo tumour growth curves as measured by tumour size of LLC, LLC-Neo and LLC-IL6 cells are shown in Figure 1 . Tumour size was calculated as the mean of the longest tumour length and width after 1 x 106 LLC, LLC-Neo or LLC-IL6 cells had been transplanted subcutaneously into the flank of C57BL/6 mice. Each group consisted of three mice. Tumour nodule was palpable 10 days after transplantation of the tumour cells in C57BL/6 mice. The growth rate of LLC-IL6 and LLC-Neo cells was similar to that of LLC cells (Figure 1 ). Figure 2 , the in vivo growth of the tumour depend on the condition of the transplanted cells. The injection of antihuman IL-6 mAb prolonged the survival of LLC-IL6 transplanted mice to 32.1 ± 2.2 days (P<0.001) ( Figure 5 ). This survival time is identical to that of untransfected LLC transplanted mice, which was 33.3 9.7 days (Figure 2 ). Macroscopical and histological examination The organs of dissected mice were macroscopically examined. Spleen weights of LLC and LLC-IL6 transplanted mice were 0.081 ± 0.047 and 0.197 ± 0.048 (P<0.05), respectively. Histologically, numerous megakaryocytes were observed in the spleen of IL-6 transplanted mice (Figure 6b) . No pathological change was observed in other organs such as liver, lung, heart and kidney. IL-6 has many functions that may be of potential benefit for patients such as anti-tumour effect and stimulation of thrombopoiesis (Mule et al., 1990; Kitahara et al., 1990; Hill et al., 1990) . However, other functions of IL-6 such as growth stimulation of myeloma, development of glomerulonephritis, induction of hypercalcaemia, inhibition of albumin synthesis may have adverse effect for patients (Bataille et al., 1989; Suematsu et al., 1989; Andus et al., 1987; Black et al., 1991) . Thus, clinical benefit of IL-6 is controversial. We have transfected IL-6 cDNA to LLC cells in the expectation to see an anti-tumour effects as reported (Mule et al., 1990; Kitahara et al., 1990 Body weight loss is commonly observed in patients with cancer and is associated with other symptoms such as anorexia, nausea, asthenia, muscle weakness and anaemia ('cancer associated cachexia') (Oliff et al., 1987; Lonnroth et al., 1990; Gelin et al., 1991) . Secretion of TNF and IL-1 from tumour cells has been reported to induce cachexia to tumour bearing mice (Oliff et al., 1987; Lonnroth et al., 1990; Gelin et al., 1991) . In a more recent report, secretion of IL-6 from Chinese hamster ovarian cells cause cachexia, hypercalcaemia, leukocytosis and thrombocytosis in tumour-bearing nude mice (Black et al., 1991) . In the present study, the survival of LLC-IL6 transplanted mice was significantly shorter than that of LLC transplanted mice without an observable difference of tumour growth and metastasis to organs such as liver, lung and lymphnode (data not shown). In addition, body weight and serum albumin were significantly lower in LLC-IL6 transplanted mice. Food and water intakes were also decreased in the group. Mouse IL-la and mouse TNF-a were not detected in the plasma of LLC-IL6 transplanted mice. Moreover, the injection of anti-IL6 mAb prolonged the survival of LLC-IL6 transplanted mice. These data suggested that LLC-IL6 transplanted mice died earlier from a state similar to cachexia induced by IL-6 itself.
The effect of IL-6 cDNA transfection to tumour cells on the survival is controversial. cDNA transfected RLY8, thymoma cell, induced a CD8+ T cells dependent immune response (Okada, 1990) . In contrast, Blankenstein et al. could not induce an immune response to IL-6 cDNA transfected J558L, myeloma cells (Blankenstein et al., 1991) . They also observed acceleration of tumour growth by IL-6 cDNA transfection which may act as an autocrine growth factor of myeloma (Blankenstein et al., 1991) . In the present study, transfection of IL-6 cDNA to tumour cells induced a state similar to cachexia and hypoalbuminemia in tumour bearing mice. We speculate that IL-6 acts to enhance T cell mediated cytotoxicity when a tumour is immunogenic in the transplanted host. Under these circumstances IL-6 producing tumour cells might be rejected by augmentation of a T cell killing without severe complications. Conversely huge amount of IL-6 is produced by established tumour cells and cause a state similar to cachexia to the mice when IL-6 producing tumour cells fail to be rejected. It is still unknown whether IL-6 directly induce hypoalbuminemia as has been reported in in vitro studies or whether a state similar to cachexia caused hypoalbuminemia secondly (Andus et al., 1987) . In LLC-IL6 transplanted mice, splenomegary was observed and many megakaryocytes were seen in the spleen without attended thrombocytosis. No pathological change was observed in liver, lung, heart and kidney, including absence of glomerulonephritis (data not shown). It is considered that several functions of IL-6 might become dominant depending on the tumour cells secreting IL-6. Thus, the clinical application of IL-6 for patients with cancer will need carefulness for adverse effects, including a state similar to cachexia.
